DIA EuroMeeting explores the road ahead for drug development in the EU and UK

Drug Information Association29 - 31 March 2017, Glasgow, United Kingdom.
DIA, (founded as the Drug Information Association) announced critical workshops to be held at the 2017 DIA EuroMeeting. The goal of the annual DIA EuroMeeting has always been to stimulate solutions by bringing together diverse stakeholder perspectives on issues affecting drug development in Europe.

Of particular importance for 2017, is the future impact of the Brexit decision across the European regulatory environment. With the European Medicines Agency (EMA) and over 1,200 QPPVs currently operating within the UK, practical solutions are needed for those roles that must legally reside in the EU. Critical stakeholders will share their perspectives on the path forward.

DIA EuroMeeting aims to bring together key healthcare stakeholder groups, such as industry, regulators, pharmacovigilance, and patients to discuss and share insights on practical solutions as well as longer term impacts of regulatory changes that need to be considered for both EU and UK citizens.

Key stakeholder group leaders include:

  • Virginia Acha, Executive Director Research, Medical and Innovation, ABPI, UK
  • Karl Broich, President, Federal Institute for Drugs and Medical Devices (BfArM), Germany
  • Elizabeth Kuiper, Director of European Affairs, EFPIA, Belgium
  • Jonathan Mogford, Director of Policy, MHRA, UK
  • Alan Morrison, Vice President Regulatory Affairs International, MSD, UK
  • Guido Rasi, Executive Director, European Medicines Agency (EMA), EU
  • Saad Shakir, Director, Drug Safety Research Unit (DSRU), UK

The 2017 EuroMeeting theme "Translational Health Care: From Bench to Bedside - and Back" also demonstrates the importance of incorporating learnings from actual patients into R&D. A new "DIAmond Session" introduces the critical theme of facilitating early patient access to innovative medicines, while the patient voice is directly incorporated in over a dozen sessions.

"Leaders across the pharmaceutical industry and regulatory agencies recognize the often conflicting goals of cost containment and accelerated access to new treatments," said Holger Adelmann, MD, PhD, Senior Vice President & Managing Director, DIA EMEA. "The path forward is achieved by multi-stakeholder collaboration, and DIA's EuroMeeting continues to be a destination for sparking these necessary conversations."

For further information, please visit:
http://www.diaglobal.org/en/flagship/euromeeting

About DIA
DIA (founded as the Drug Information Association) provides is a global, neutral forum where stakeholders can openly and freely exchange knowledge information and insights beyond boundaries to advance innovation in health care product development and lifecycle management globally. DIA is an international, nonprofit, multidisciplinary member association that provides health care product development professionals a neutral and transparent forum for collaboration and the exchange of insights to improve health globally through the advancement of lifesaving medicines and technologies. DIA builds knowledge through, learning solutions (digital and in person training), conferences and insights in the areas of, Regulatory Science, Translational Medicine, Patient Engagement and Value and Access for professionals in the pharmaceutical, biotechnology, and medical device communities.

Most Popular Now

FDA approves Roche's OCREVUS™ (ocrelizumab) for re…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) approved OCREVUS™ (ocrelizumab) as the first and only medicine for both ...

Read more

First collaborative definition of patient centrici…

AstraZeneca announced that BMJ Innovations has published the first collaborative definition of patient centricity for the pharmaceutical industry. The definition was co-d...

Read more

High doses of vitamin C to improve cancer treatmen…

Clinical trials found that it is safe to regularly infuse brain and lung cancer patients with 800 - 1000 times the daily recommended amount of vitamin C as a potential st...

Read more

Deep learning algorithm could boost drug developme…

Artificially intelligent algorithms can learn to identify amazingly subtle information, enabling them to distinguish between people in photos or to screen medical images ...

Read more

Bristol-Myers Squibb enters into separate agreemen…

Bristol-Myers Squibb Company (NYSE:BMY) today announced that it has entered into two separate agreements to license BMS-986168, an anti-eTau compound in development for ...

Read more

Tagrisso (osimertinib) receives US FDA full approv…

AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted full approval for Tagrisso (osimertinib) 80mg once-daily tablets, for the treatment...

Read more

A one-two punch hits pancreatic cancer where it hu…

Australian scientists have uncovered a promising new approach to treating pancreatic cancer, by targeting the tissue around the tumour to make it 'softer' and more respon...

Read more

FDA allows marketing of first direct-to-consumer t…

The U.S. Food and Drug Administration today allowed marketing of 23andMe Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases or conditions. These are ...

Read more

Novartis to strengthen R&D pipeline by in-lice…

Novartis has exercised an option to in-license ECF843 for ophthalmic indications worldwide (outside Europe). The closing of the deal is subject to customary closing condi...

Read more

New drug delivery system shows promise for fightin…

A new cancer-drug delivery system shows the ability to exploit the oxygen-poor areas of solid tumors that make the growths resistant to standard chemotherapy and radiatio...

Read more

Towards a safe and scalable cell therapy for type …

More than 36 million people globally are affected by type 1 diabetes (T1D), a lifelong disorder where insulin producing cells are attacked and destroyed by the immune sys...

Read more

XELJANZ® (tofacitinib citrate) receives marketing …

Pfizer Inc. (NYSE:PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 5 mg twice daily (BID) oral tablets in combination wi...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]